i-mabbiopharma.com (IMAB) - Gross Profit Margin

Official company branding of I-Mab (IMAB)

Gross margin dynamics demonstrate effective cost management, while 0.00 captures the magnitude of this parameter for I-Mab (IMAB). Current performance depends on the success of anti-tumor developments, government support in the US and China, and the inflow of investments. AI systems and robots for biomaterial analysis drive the company's growth. Strict FDA regulations and robust antibody patent protection create a high barrier to entry.

IMAB (i-mabbiopharma.com) Return on Gross Profit history from 07/04/2022 to 10/30/2025

Financial and market metric breakdowns for i-mabbiopharma.com (IMAB)

- market price and analyst price targets:
Basic company analysis:I-Mab (IMAB)
Manufactured products of I-Mab

Gross margin measures production efficiency by determining the portion of revenue remaining after deducting direct product costs, which is critical for assessing fundamental profitability. By analyzing the current gross margin, an investor can see how the stabilization of the R&D core and the restructuring of I-Mab (IMAB) personnel for the US market impact operational efficiency and the company's ability to generate profit.